Paula Cobb
Direktor/Vorstandsmitglied bei PROTHENA CORPORATION PLC
Vermögen: - $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Gene Kinney | M | 55 | 12 Jahre | |
Lars Ekman | M | 74 | 12 Jahre | |
Daniel Welch | M | 66 | - | |
Caroline Dorsa | F | 64 | 14 Jahre | |
Tran Nguyen | M | 50 | 11 Jahre | |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Richard Collier | M | 70 | 12 Jahre | |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
Wagner M. Zago | M | 51 | 12 Jahre | |
Randy Fawcett | M | - | - | |
Stephen Sherwin | M | 75 | 14 Jahre | |
Michael J. Malecek | M | 58 | 5 Jahre | |
Helen Elizabeth Hanby | F | 58 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | - |
Michael Hencke | M | - | 12 Jahre | |
Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
Nicole Murphy | F | - | 9 Jahre | |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Brandon Smith | M | 50 | 4 Jahre | |
Oleg Nodelman | M | 47 | 5 Jahre | |
Susan Alexander | F | 67 | 21 Jahre | |
Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Eric Rowinsky | M | 67 | 14 Jahre | |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Dennis Selkoe | M | 80 | 11 Jahre | |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Shane Cooke | M | 61 | 12 Jahre | |
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Yvonne M. Tchrakian | F | - | 10 Jahre | |
Michael Bachner | M | - | 2 Jahre | |
Botond Roska | M | 54 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Robert May | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Petra Kaufmann | M | 58 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
Laura Richman | M | 60 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Aaron Tward | M | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Helen Kim | F | 61 | 2 Jahre | |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
Carol Karp | F | 71 | 8 Jahre | |
Karin Walker | F | 60 | 11 Jahre | |
Lori Elizabeth Mochan | F | 47 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | - |
Diana Brainard | M | 53 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 2 Jahre |
Hideki Garren | M | 60 | 3 Jahre | |
Michael Dambach | M | 57 | 17 Jahre | |
William Dunn | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
George Scangos | M | 76 | 7 Jahre | |
Trevor Anthony Mill | M | 53 | 9 Jahre | |
William Rastetter | M | 75 | 19 Jahre | |
Stelios Papadopoulos | M | 75 | 15 Jahre | |
James Mullen | M | 65 | 21 Jahre | |
William Young | M | 79 | 11 Jahre | |
Bryan Yoon | M | 46 | 2 Jahre | |
Jennifer Zibuda | F | - | 3 Jahre | |
Douglas Kerr | M | 57 | 2 Jahre | |
James McArthur | M | 62 | 3 Jahre | |
Senthil Sundaram | M | 46 | 2 Jahre | |
Robert A. Hamm | M | 72 | 7 Jahre | |
Chris Hollowood | M | 50 | 6 Jahre | |
John Lee | M | 56 | 5 Jahre | |
Gilmore O’Neill | M | 59 | 15 Jahre | |
Neil Exter | M | 65 | 5 Jahre | |
Lynne Sullivan | F | 58 | 10 Jahre | |
Sanjiv Patel | M | 50 | 2 Jahre | |
Richard Mulligan | M | 69 | 14 Jahre | |
Eric S. Hoffman | M | 54 | 5 Jahre | |
Karl Härfstrand | M | 66 | 9 Jahre | |
Joseph Mara | M | 49 | - | |
Gregory Covino | M | 59 | 6 Jahre | |
David Lubner | M | 60 | 2 Jahre | |
Gina Consylman | F | 52 | 3 Jahre | |
Ronald Vigliotta | M | 51 | 5 Jahre | |
Nancy L. Leaming | F | 76 | 14 Jahre | |
Craig Eric Schneier | M | 76 | 8 Jahre | |
Michael Gilman | M | 69 | 8 Jahre | |
Scott Whitcup | M | 64 | 2 Jahre | |
Carlos Costa | M | 51 | 7 Jahre | |
Christine Poon | F | 71 | 2 Jahre | |
Sylvie Grégoire | M | 62 | 8 Jahre | |
David Mott | M | 58 | 4 Jahre | |
Phillip Sharp | M | 79 | 31 Jahre | |
Christopher Henney | M | 83 | 9 Jahre | |
Brian Posner | M | 62 | 14 Jahre | |
Alexander Denner | M | 54 | 14 Jahre | |
Samantha Truex | F | - | 8 Jahre | |
Ritika Mahal | F | - | 3 Jahre | |
Dell Faulkingham | M | 51 | 9 Jahre | |
Andrea DiFabio | F | 55 | 11 Jahre | |
Mark Wiggins | M | 68 | 11 Jahre | |
Matthew P. Ottmer | M | 53 | 16 Jahre | |
Richard Ransohoff | M | - | 3 Jahre | |
Donald R. Johns | M | - | 2 Jahre | |
Olivier Danos | M | 66 | 3 Jahre | |
Allen Kamer | M | 53 | 3 Jahre | |
John Leonard | M | 77 | 15 Jahre | |
Kiran Reddy | M | 47 | 2 Jahre | |
Timothy Harris | M | 74 | 1 Jahre | |
Melissa Morandi | F | 59 | 2 Jahre | |
Connie Matsui | F | 70 | 18 Jahre | |
Stephen Tulipano | M | 65 | 8 Jahre | |
Robert Perez | M | 59 | 8 Jahre | |
Bonne Adams | F | 47 | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 68 | 68,00% |
Irland | 23 | 23,00% |
Vereinigtes Königreich | 10 | 10,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Paula Cobb
- Persönliches Netzwerk